| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
18,540,000 |
| Market
Cap: |
282.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.08 - $33.01 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Co.'s proprietary platform technology, BAROSTIM®, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System (ANS) which causes heart failure (HF) and other cardiovascular diseases. Co.'s second-generation product, BAROSTIM NEO®, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HF and resistant hypertension.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
78,953 |
| Total Buy Value |
$0 |
$0 |
$0 |
$437,064 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
6,270 |
6,270 |
8,020 |
12,620 |
| Total Sell Value |
$151,890 |
$151,890 |
$183,171 |
$238,102 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
2 |
4 |
5 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Palmer Craig E. |
SVP, U.S. SALES |
• – – |
2024-03-25 |
4 |
OE |
$0.24 |
$221 |
D/D |
934 |
1,229 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
|
– – • |
2024-02-29 |
4 |
OE |
$0.24 |
$2,792 |
I/I |
3,855 |
4,103,430 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,650 |
805 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-20 |
4 |
S |
$21.91 |
$55,748 |
D/D |
(2,545) |
2,455 |
|
26% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-20 |
4 |
OE |
$5.14 |
$25,705 |
D/D |
5,000 |
5,000 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
|
– – • |
2024-02-16 |
4 |
S |
$25.81 |
$96,142 |
I/I |
(3,725) |
4,099,575 |
|
28% |
|
| Johnson & Johnson Development Corp Et Al |
|
– – • |
2024-02-16 |
4 |
OE |
$0.16 |
$96,021 |
I/I |
607,725 |
4,103,300 |
|
- |
|
| Yared Nadim |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-01-29 |
4 |
OE |
$0.24 |
$1,422 |
D/D |
6,000 |
26,255 |
|
- |
|
| Slattery Joseph P |
|
– • – |
2023-12-28 |
4 |
OE |
$0.24 |
$984 |
D/D |
1,950 |
22,145 |
|
- |
|
| Behbahani Ali |
Director |
– • – |
2023-12-14 |
4 |
OE |
$0.24 |
$75 |
D/D |
316 |
316 |
|
- |
|
| Galle Liz |
VP OF GLOBAL CLINICAL RESEARCH |
• – – |
2023-10-16 |
4 |
OE |
$0.24 |
$184 |
D/D |
778 |
778 |
|
- |
|
| Oasheim Jared |
CHIEF FINANCIAL OFFICER |
• – – |
2023-09-18 |
4 |
OE |
$0.24 |
$21,225 |
D/D |
5,862 |
15,447 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2023-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,495,575 |
|
93% |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2023-09-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,495,575) |
0 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2023-08-03 |
4 |
S |
$18.55 |
$11,652 |
D/D |
(628) |
0 |
|
-29% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2023-08-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
628 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2023-07-31 |
4 |
S |
$17.49 |
$19,629 |
D/D |
(1,122) |
2,628 |
|
-26% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2023-07-31 |
4 |
OE |
$5.14 |
$19,279 |
D/D |
3,750 |
3,750 |
|
- |
|
| Palmer Craig E. |
SVP, U.S. SALES |
• – – |
2023-05-16 |
4 |
OE |
$0.24 |
$70 |
D/D |
295 |
295 |
|
- |
|
| Yared Nadim |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-01-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,080 |
20,255 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2022-11-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,400 |
0 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2022-11-28 |
4 |
S |
$11.85 |
$54,931 |
D/D |
(4,600) |
4,400 |
|
22% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2022-11-28 |
4 |
OE |
$5.14 |
$46,269 |
D/D |
9,000 |
9,000 |
|
- |
|
| Oasheim Jared |
CHIEF FINANCIAL OFFICER |
• – – |
2022-06-02 |
4 |
OE |
$0.24 |
$2,272 |
D/D |
9,585 |
9,585 |
|
- |
|
| Nielsen Kirk G. |
Director |
– • – |
2022-05-24 |
4 |
B |
$5.05 |
$40,752 |
I/I |
8,070 |
1,711,355 |
2.1 |
81% |
|
66 Records found
|
|
Page 1 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.12 (6.84%) 
